List of Excipients in Branded Drug EQUATE CIMETIDINE

Generic Drugs Containing EQUATE CIMETIDINE

Company	Ingredient	NDC	Excipient
Wal-Mart Stores Inc	cimetidine	49035-820	CELLULOSE, MICROCRYSTALLINE
Wal-Mart Stores Inc	cimetidine	49035-820	HYPROMELLOSE
Wal-Mart Stores Inc	cimetidine	49035-820	MAGNESIUM STEARATE
Wal-Mart Stores Inc	cimetidine	49035-820	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in EQUATE CIMETIDINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL

Equate Cimetidine Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Equate cimetidine is an over-the-counter, immediate-release acid-reducer product positioned around low-cost treatment of heartburn and excess stomach acid. Its commercial advantage does not depend on molecule-level exclusivity. It depends on dependable tablet manufacture, low excipient cost, shelf stability, retailer economics, and compliance with the FDA OTC framework.

The highest-value opportunities are differentiated dosage forms, smaller package sizes, private-label supply, hospital and institutional channels, and reformulations that improve swallowing or dosing convenience. A new oral product would face limited patent risk because cimetidine is an old, off-patent active ingredient. The main barriers are FDA compliance, supplier qualification, stability, taste, manufacturing scale, and retailer access.

What is Equate cimetidine and how is it regulated?

Equate cimetidine is a Walmart private-label product containing cimetidine, an H2-receptor antagonist used to reduce gastric acid and relieve heartburn. The commonly marketed product is a 200 mg oral tablet intended for OTC use.

Attribute	Equate cimetidine
Brand owner	Walmart, through the Equate private-label platform
Active ingredient	Cimetidine
Common strength	200 mg
Dosage form	Immediate-release oral tablet
Therapeutic category	OTC H2-receptor antagonist
Primary indication	Heartburn associated with acid indigestion
Regulatory route	OTC monograph pathway, subject to current FDA requirements
Biosimilar exposure	None
Generic substitution	Relevant at the active-ingredient and dosage-form level
Patent dependence	Low
Principal commercial constraint	Price, retail distribution, and manufacturing economics

Cimetidine is an established H2 blocker. Unlike prescription products that rely on new-drug applications, biologic licenses, or active patent estates, an OTC cimetidine product generally competes through compliance and cost.

FDA’s OTC monograph system establishes permitted active ingredients, indications, labeling, dosage, and conditions for nonprescription marketing. The relevant framework for acid-reducing products includes FDA requirements for H2-receptor antagonist products and OTC labeling under the Federal Food, Drug, and Cosmetic Act (FDA, 2020a; FDA, 2023).

What excipients are likely used in Equate cimetidine tablets?

The exact Equate formulation should be determined from the current package label, DailyMed entry, or product-specific regulatory filing. Private-label manufacturers can change excipient suppliers and manufacturing sites without changing the consumer-facing brand.

A conventional cimetidine tablet is likely to use the following excipient functions:

Excipient function	Common candidate materials	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Adjusts tablet weight and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes breakup after ingestion
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Film former	Hypromellose	Supports coating and appearance
Plasticizer	Polyethylene glycol or similar material	Improves coating flexibility
Colorant	Approved iron oxide or other permitted colorant	Supports product identification
Opacifier	Titanium dioxide, where permitted and used	Controls tablet appearance
Sweetener or flavor	More relevant to chewable or liquid formats	Masks cimetidine taste

The preferred formulation is usually a direct-compression or dry-granulation system. That approach limits water exposure, reduces manufacturing steps, and supports low unit cost. The selection depends on cimetidine’s bulk density, flow, compactability, particle-size distribution, and compatibility with lubricants and coating systems.

What excipient characteristics matter most for cimetidine?

Cimetidine is a relatively high-dose small molecule compared with many modern oral drugs. That makes excipient loading and tablet size commercially important. A formulation that uses excessive filler can produce a large tablet, while insufficient binder or disintegrant can create friability or delayed dissolution.

The main development targets are:

1. Tablet weight low enough for consumer acceptability.
2. Mechanical strength suitable for high-speed bottling and blistering.
3. Rapid disintegration and dissolution in the intended release profile.
4. Low lubricant sensitivity.
5. Low moisture uptake during storage.
6. Minimal interaction with coating pigments and packaging materials.
7. Consistent appearance across contract-manufacturing sites.

A low-cost formulation should favor widely available compendial excipients with multiple qualified suppliers. Microcrystalline cellulose, starch-based excipients, crospovidone, colloidal silicon dioxide, and magnesium stearate are commercially attractive because they are globally available and supported by established pharmaceutical supply chains.

How should an excipient strategy be designed for Equate cimetidine?

The strongest strategy is a simple immediate-release platform with controlled manufacturing variability rather than a heavily engineered formulation.

Direct compression versus wet granulation

Direct compression can lower labor, water use, cycle time, and validation burden. It is attractive for a high-volume OTC product if the active ingredient and excipient blend have adequate flow and compactability.

Wet granulation may be justified when the powder blend has poor flow, segregation risk, or insufficient tablet strength. It adds processing cost and introduces water and drying controls. For cimetidine, a wet-granulated formula may improve robustness but would need to justify the additional cost against a low-price retail product.

Dry granulation is a middle option. Roller compaction can improve bulk density and flow while limiting water exposure. It may be useful when direct compression produces excessive tablet weight or batch-to-batch variability.

Manufacturing platform	Cost profile	Technical benefit	Fit for Equate
Direct compression	Lowest	Short process and low equipment burden	Strong if powder properties are acceptable
Dry granulation	Moderate	Improves density and flow without water	Strong for scale-up flexibility
Wet granulation	Highest	Broad control over flow and compressibility	Useful only where performance requires it

Coating and packaging

Film coating can improve swallowability, mask taste, reduce powdering, and create brand identification. It also increases cost and may slow production. For a low-price 200 mg tablet, an uncoated or lightly coated tablet can be economically rational if stability and consumer acceptance are adequate.

Packaging is part of the excipient and stability strategy. Bottles with induction seals and desiccants can support low-cost distribution. Blister packaging can improve unit-dose protection and portability but typically carries higher packaging cost. A moisture-sensitive formula may justify high-barrier blister material despite the added expense.

What formulations are protected or commercially differentiated?

There is little commercial value in trying to protect conventional cimetidine tablets through broad composition claims. The active ingredient and basic immediate-release tablet technology are mature. Any meaningful differentiation would likely arise from dosage form, release profile, taste masking, packaging, or a specialized patient population.

Potential formulation targets include:

Product concept	Commercial rationale	Development risk
Chewable cimetidine tablet	Avoids swallowing difficulty and supports on-the-go use	Strong taste-masking requirement
Orally disintegrating tablet	Targets consumers with dysphagia	Requires robust mechanical and moisture control
Effervescent tablet or powder	Rapid dispersion and convenience	Packaging, taste, and stability challenges
Liquid or suspension	Pediatric and geriatric utility	Preservative, viscosity, and microbial controls
Smaller-dose tablet	Supports flexible dosing	May reduce manufacturing efficiency
Combination acid-reducer product	Broader symptom positioning	More complex regulatory and compatibility review
Unit-dose blister	Travel and adherence benefit	Higher packaging cost
Sugar-free chewable	Expands diabetic-conscious positioning	Requires acceptable sweetener and mouthfeel

The most practical opportunity is a chewable or orally disintegrating product with effective taste masking. Cimetidine has a noticeable taste profile, so the excipient system would need a sweetener, flavor, saliva-compatible binder, and a coating or polymer barrier that limits immediate drug exposure in the mouth.

When does cimetidine lose exclusivity?

Cimetidine lost meaningful U.S. market exclusivity many years ago. The original Tagamet franchise was based on an old small-molecule product and historical patent protection associated with cimetidine and its pharmaceutical uses. Those rights are no longer a material barrier to OTC entry.

Exclusivity category	Current relevance to Equate cimetidine
New chemical entity exclusivity	Expired
Pediatric exclusivity	Not a current barrier
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Active ingredient patent protection	No material current barrier identified
Formulation patent risk	Limited for conventional immediate-release tablets
Method-of-use patent risk	Limited for ordinary OTC heartburn use
OTC monograph access	Primary regulatory pathway

Because cimetidine is a small molecule, there is no biosimilar pathway. Competition occurs through generic, OTC-monograph, private-label, and branded products.

What is the Orange Book status of Equate cimetidine?

A conventional OTC-monograph cimetidine product is generally not dependent on an Orange Book-listed new-drug application in the way a prescription NDA product is. The Orange Book is principally relevant to approved prescription and certain nonprescription drug applications, including patent and exclusivity information submitted for those applications (FDA, 2024).

The practical implication is that an OTC-monograph product normally does not create an Orange Book Paragraph IV litigation pathway comparable to a patented prescription drug.

Issue	Equate cimetidine impact
Orange Book patent listing	Not normally central for an OTC-monograph product
Paragraph IV certification	Generally not the principal entry mechanism
ANDA litigation	Unlikely to be the main commercial pathway
OTC monograph compliance	Central
Drug Facts labeling	Mandatory
Manufacturing controls	Required under current good manufacturing practice

Which companies are challenging Equate cimetidine?

Publicly available information does not indicate a material patent challenge directed specifically at Equate cimetidine. The product is a private-label OTC medicine and does not appear to depend on a significant active patent estate.

The competitive set is broader than named litigants. It includes:

• National brands such as Tagamet and other cimetidine products.
• Store-brand cimetidine products sold through other retailers.
• Generic manufacturers.
• Alternative H2 blockers such as famotidine.
• Proton-pump inhibitor products such as omeprazole and lansoprazole.
• Antacid products containing calcium carbonate, magnesium hydroxide, or aluminum hydroxide.

The largest competitive threat is substitution, not patent litigation. Consumers may select famotidine because of stronger brand recognition, longer duration of action, or broader current retail availability.

What generic entry risks exist for Equate cimetidine?

Generic entry risk is structurally high because the product contains an old, readily available active ingredient and uses a conventional oral dosage form. Equate’s defense is not exclusivity. It is purchasing scale, shelf placement, retail data, supplier reliability, and low landed cost.

Key risks include:

Risk	Effect on Equate
Retail price compression	Reduces gross margin
Store-brand duplication	Creates internal or external shelf competition
Active-ingredient supply disruption	Causes stockouts or manufacturing delays
Excipient shortages	Forces rapid reformulation or supplier changes
Famotidine substitution	Erodes demand
Consumer migration to PPIs	Reduces category volume
Product-quality event	Can trigger retailer delisting and recall costs
Labeling changes	Requires packaging and inventory replacement

A manufacturer that can match the reference product’s dissolution, appearance, bottle count, and unit economics can enter with limited technical differentiation.

How strong is the patent estate for Equate cimetidine?

The patent estate is weak as a commercial defense and largely irrelevant to the value proposition. Cimetidine’s strategic value lies in regulatory simplicity and manufacturing scale rather than patent exclusivity.

Patent category	Strength for Equate
Active ingredient	Very weak
Conventional tablet composition	Weak
Immediate-release process	Weak unless narrowly engineered
Chewable taste masking	Potentially moderate
ODT structure	Potentially moderate, but crowded
Packaging configuration	Low to moderate
Specialized combination product	Potentially moderate
Method of use	Low for ordinary heartburn indications

A new excipient composition could receive patent protection only if it demonstrates a non-obvious technical effect, such as substantially improved taste masking, dissolution stability, moisture resistance, or patient usability. Routine substitution of one standard filler or disintegrant for another would have limited patent value.

What commercial opportunities exist for Equate cimetidine?

Private-label manufacturing

Contract manufacturers can compete for Equate supply by offering:

• Lower conversion cost.
• Multi-site manufacturing resilience.
• Validated direct-compression platforms.
• Flexible bottle counts and blister formats.
• Dual-source excipient qualification.
• Reliable FDA inspection history.
• Fast change control for packaging and labeling.

The strongest opportunity is a platform approach that can manufacture cimetidine alongside other OTC tablets using common excipients and equipment.

Formulation extensions

A chewable product is the most commercially credible extension. It could target consumers who avoid swallowing tablets, but it would need strong taste masking and a pleasant mouthfeel. A sugar-free version could use polyols or high-intensity sweeteners, although polyols may affect tablet compression and gastrointestinal tolerability.

An orally disintegrating tablet could command a modest premium if it provides clear convenience. Its business case is weaker if the product becomes too moisture-sensitive or requires costly high-barrier packaging.

Institutional and travel formats

Unit-dose blister packs can target travel, workplace first-aid supplies, hotels, and institutional cabinets. Smaller packages reduce inventory exposure and may improve trial conversion. Larger-count bottles can support family use and lower per-dose packaging costs.

Geographic expansion

Cimetidine is widely recognized internationally, but regulatory status, permitted claims, labeling, and OTC availability vary by country. Expansion opportunities depend on local classification, approved indications, and local-language labeling. The commercial model should prioritize jurisdictions where H2 blockers remain available OTC and where retailer private-label penetration is high.

Revenue exposure

Equate-specific revenue is not publicly reported separately by Walmart. Revenue should therefore be modeled from sell-through assumptions rather than inferred from Walmart’s consolidated filings. The relevant variables are:

• Unit count per package.
• Retail price.
• Store count and online availability.
• Annual unit velocity.
• Promotional discounting.
• Wholesale or transfer price.
• Retailer gross-margin requirements.
• Share relative to famotidine and PPI products.

The product is likely to be a low-revenue-per-unit, high-volume asset. Margin expansion depends more on procurement and packaging redesign than on price increases.

What litigation, licensing, and settlement issues affect Equate cimetidine?

No material current patent litigation, Paragraph IV dispute, or settlement agreement is central to conventional Equate cimetidine marketing. The likely commercial relationship is a private-label supply arrangement between Walmart and one or more contract manufacturers.

Such arrangements are usually governed by quality agreements, supply commitments, specifications, audit rights, change-control provisions, recall allocation, indemnification, and service-level requirements. These contractual terms can be more commercially important than patent rights.

Manufacturing IP may still matter where a supplier has proprietary taste-masking systems, continuous-compression processes, specialized coating equipment, or validated high-speed packaging methods. Those rights could support supplier differentiation, but they would not create broad exclusivity for cimetidine.

What is the best commercial strategy for an Equate cimetidine successor?

The most defensible strategy is a low-cost, quality-controlled tablet platform supported by a differentiated secondary format.

1. Maintain a conventional 200 mg immediate-release tablet as the volume product.
2. Use a compact, low-moisture formulation with dual-sourced excipients.
3. Evaluate direct compression before adopting granulation.
4. Add a chewable or ODT line only after taste masking and stability targets are met.
5. Use package-size segmentation to support value, trial, and travel channels.
6. Preserve manufacturing flexibility across at least two qualified sites.
7. Avoid relying on patent exclusivity.
8. Protect any differentiated formulation through narrow composition, process, and use claims where the data support patentability.
9. Monitor famotidine and PPI pricing because substitution is the primary demand risk.
10. Treat quality, recall readiness, and retailer service levels as core commercial assets.

Key Takeaways

• Equate cimetidine is a mature OTC private-label product with low patent dependence.
• The likely core product is a 200 mg immediate-release oral tablet.
• Excipient selection should prioritize compression, rapid disintegration, low moisture sensitivity, supplier redundancy, and unit cost.
• Exact inactive ingredients can change by manufacturer and package presentation.
• Conventional cimetidine tablets have limited formulation patent value.
• The product is not exposed to biosimilar competition.
• Paragraph IV litigation is generally not the principal entry risk for an OTC-monograph product.
• The largest threats are price compression, store-brand competition, famotidine substitution, PPI migration, and supply disruption.
• Chewable, ODT, sugar-free, liquid, and unit-dose formats offer the clearest commercial extensions.
• Contract manufacturing scale and retailer execution are more important than patent exclusivity.

FAQs

Is cimetidine still commercially attractive as an OTC product?

Yes, but primarily as a high-volume, low-cost private-label product. Its attractiveness depends on manufacturing efficiency, retail distribution, and category demand rather than innovation premiums.

Can a new cimetidine excipient composition be patented?

Possibly, but only where the formulation produces a non-obvious technical result. Routine use of standard fillers, binders, lubricants, or disintegrants is unlikely to support a strong patent position.

Is cimetidine interchangeable with famotidine?

Both are H2-receptor antagonists, but they are not automatically interchangeable on a milligram-for-milligram basis. Labeling, dosing, duration, interactions, and regulatory claims must be evaluated separately.

Which excipient is most important in a cimetidine chewable tablet?

Taste-masking components are commercially decisive. Sweeteners, flavors, polymeric barriers, and mouthfeel modifiers must work together without compromising dissolution, tablet strength, or stability.

Could Equate cimetidine be relaunched as an orally disintegrating tablet?

Yes. The concept is technically feasible, but moisture protection, taste masking, mechanical strength, and packaging cost would determine whether the format produces a viable retail margin.

References

1. U.S. Food and Drug Administration. (2020a). OTC monograph M005: Antacid products. https://www.fda.gov
2. U.S. Food and Drug Administration. (2020b). Over-the-counter monograph system. https://www.fda.gov
3. U.S. Food and Drug Administration. (2023). Drug Facts labeling for nonprescription human drug products. https://www.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.